{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137046239388928.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1186/2051-1426-2-14"}}],"dc:title":[{"@value":"Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137046239388931","@type":"Researcher","foaf:name":[{"@value":"Raju R Raval"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137046239388930","@type":"Researcher","foaf:name":[{"@value":"Andrew B Sharabi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137046239388928","@type":"Researcher","foaf:name":[{"@value":"Amanda J Walker"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137046239388932","@type":"Researcher","foaf:name":[{"@value":"Charles G Drake"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137046239388929","@type":"Researcher","foaf:name":[{"@value":"Padmanee Sharma"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"20511426"}],"prism:publicationName":[{"@value":"Journal for ImmunoTherapy of Cancer"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2014","prism:volume":"2","prism:number":"1","prism:startingPage":"14"},"reviewed":"false","createdAt":"2014-05-14","modifiedAt":"2020-09-25","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168099464960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846644845087872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1186/2051-1426-2-14"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.21602_references_DOI_WDuslsSqfRIU4bFSbtk4qKkBWKt"},{"@type":"CROSSREF","@value":"10.1111/cas.12695_references_DOI_WDuslsSqfRIU4bFSbtk4qKkBWKt"}]}